2024 was a mixed year for biopharma stocks, with the iShares Biotechnology ETF and SPDR S&P Biotech ETF experiencing small decreases. Federal Reserve decisions caused a 10-day decline in biotech ETFs. StockWatch’s top five performing biotech stocks include Bright Minds Biosciences and Monopar Therapeutics while the biggest laggards were Aditxt and CNS Pharmaceuticals. Mesoblast’s American Depositary Receipts rose significantly due to FDA approval of its Ryoncil treatment.
Santee offering few details about cyber attack or contract to recover data – The San Diego Union-Tribune
Santee has provided limited information about a cyber attack and the contract they signed to recover data. The city has not disclosed many details about
